BioCentury
ARTICLE | Clinical News

Rayaldee calcifediol regulatory update

June 27, 2016 7:00 AM UTC

FDA approved an NDA from Opko for Rayaldee calcifediol to treat secondary hyperparathyroidism (SHPT) in patients with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency. Opko plans to launch the product next half. ...